"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...
Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potentially ...
(AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive ...
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
or HER2-ultralow metastatic breast cancer. The FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as the first HER2-directed therapy for adult patients with ...
chemotherapy with a median progression-free survival of more than one year Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu to an earlier HR-positive treatment setting and broadens the patient ...
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...
The company’s PATHWAY HER2 antibody test—used to help screen patients for treatment with Enhertu (trastuzumab deruxtecan-nxki), the antibody-drug conjugate jointly developed by Daiichi Sankyo ...
Narrow-moat Daiichi Sankyo’s third-quarter earnings were in ... Enhertu just received US approval for indication expansion into HER2-low or HER2-ultralow chemo-naïve patients in January ...
We will now would like to start Daiichi Sankyo's Financial Results Briefing ... Fiscal year 2024 Q3 year-to-date sales grew led by HER2+ breast cancer second line treatment and chemotherapy ...